Premium
Testing times! Choosing Wisely when it comes to monitoring type 2 diabetes
Author(s) -
Speight Jane,
Browne Jessica L,
Furler John S
Publication year - 2015
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja15.00639
Subject(s) - research centre , library science , citation , diabetes mellitus , sociology , medicine , computer science , endocrinology
The Cochrane review included 12 RCTs (3249 participants). Among these, nine trials of 6 months’ duration found that glycated haemoglobin (HbA1c) levels were reduced on average by 0.3% (a statistically, but not clinically, significant improvement). There was no significant reduction in HbA1c levels in trials with 12 months of follow-up. Overall, no benefit was shown for patient satisfaction, emotionalwellbeingor health-related quality of life, and SMBG was considered unlikely to be cost-effective.